Related Experiment Video
Updated: Apr 30, 2026

Assays for the Specific Growth Rate and Cell-binding Ability of Rotavirus
Published on: January 28, 2019
Rotavirus vaccination in Europe: drivers and barriers
N Parez1, C Giaquinto2, C Du Roure3
1Service de Pédiatrie, Hôpital Louis Mourier, Colombes, France.
Abstract:
Rotavirus gastroenteritis is a vaccine-preventable disease that confers a high medical and economic burden in more developed countries and can be fatal in less developed countries. Two vaccines with high efficacy and good safety profiles were approved and made available in Europe in 2006. We present an overview of the status of rotavirus vaccination in Europe. We discuss the drivers (including high effectiveness and effect of universal rotavirus vaccination) and barriers (including low awareness of disease burden, perception of unfavourable cost-effectiveness, and potential safety concerns) to the implementation of universal rotavirus vaccination in Europe. By February, 2014, national universal rotavirus vaccination had been implemented in Belgium, Luxembourg, Austria, Finland, Greece, Luxembourg, Norway, and the UK. Four other German states have issued recommendations and reimbursement is provided by sickness funds. Other countries were at various stages of recommending or implementing universal rotavirus vaccination.
Related Concept Videos
Vaccinations
Vaccines
Microorganisms in Medicine and Therapeutics
Vaccine Production
Size and Structure of Viral Genomes
Bacterial Gastroenteritis

